Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
152 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Foot Ulcers - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Diabetic Foot Ulcers - Pipeline Review, H1 2015', provides an overview of the Diabetic Foot Ulcers's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Foot Ulcers and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Foot Ulcers pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Diabetic Foot Ulcers Overview 8 Therapeutics Development 9 Pipeline Products for Diabetic Foot Ulcers - Overview 9 Pipeline Products for Diabetic Foot Ulcers - Comparative Analysis 10 Diabetic Foot Ulcers - Therapeutics under Development by Companies 11 Diabetic Foot Ulcers - Therapeutics under Investigation by Universities/Institutes 15 Diabetic Foot Ulcers - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Diabetic Foot Ulcers - Products under Development by Companies 20 Diabetic Foot Ulcers - Products under Investigation by Universities/Institutes 23 Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 24 Adocia 24 Aprogen, Inc. 25 CardioVascular BioTherapeutics, Inc. 26 Celgene Corporation 27 CoDa Therapeutics, Inc. 28 CytoTools AG 29 Derma Sciences, Inc. 30 Dipexium Pharmaceuticals LLC 31 EyeGene, Inc. 32 FirstString Research, Inc. 33 GlaxoSmithKline plc 34 Innovaxis 35 Izun Pharmaceuticals Corporation 36 Karyopharm Therapeutics, Inc. 37 Kasiak Research Pvt. Ltd. 38 Lumosa Therapeutics Co., Ltd. 39 Lytix Biopharma AS 40 MacroCure Ltd. 41 MediaPharma s.r.l. 42 NovaLead Pharma Pvt. Ltd. 43 Oneness Biotech Co., Ltd. 44 Plurogen Therapeutics, Inc. 45 Reliance Life Sciences Pvt. Ltd. 46 Royer Biomedical, Inc. 47 Sanofi 48 Stratatech Corporation 49 TechnoPhage SA 50 Tissue Med Biosciences 51 USV Limited 52 Vyome Biosciences Private Limited 53 Diabetic Foot Ulcers - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Target 55 Assessment by Mechanism of Action 57 Assessment by Route of Administration 59 Assessment by Molecule Type 61 Drug Profiles 63 aclerastide - Drug Profile 63 ALLO-ASC - Drug Profile 65 AP-102 - Drug Profile 66 APO-2 - Drug Profile 67 becaplermin - Drug Profile 68 Biochaperone PDGF-BB - Drug Profile 69 Cathelicidin - Drug Profile 71 Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 73 CL-05 - Drug Profile 74 CODA-001 - Drug Profile 76 CSTC-1 - Drug Profile 78 CureXcell - Drug Profile 79 CVBT-141B - Drug Profile 80 Cyndacel-M - Drug Profile 82 daprodustat - Drug Profile 83 Drug for Diabetic Foot Ulcer - Drug Profile 85 EG-Decorin - Drug Profile 86 epidermal growth factor biosimilar - Drug Profile 87 esmolol hydrochloride - Drug Profile 88 Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 89 gentamicin sulfate - Drug Profile 90 Granexin - Drug Profile 91 Heberprot-P - Drug Profile 92 IMSP-001 - Drug Profile 93 IZN-6D4 - Drug Profile 94 LTX-109 - Drug Profile 95 MPHE-001A - Drug Profile 97 MT-003 - Drug Profile 98 Mul-1867 - Drug Profile 99 Nu-2 - Drug Profile 100 Nu-3 - Drug Profile 101 ON-101 - Drug Profile 102 PDA-002 - Drug Profile 103 pexiganan acetate - Drug Profile 104 PluroGel N - Drug Profile 106 Refaheal - Drug Profile 107 ReliDerm-DT - Drug Profile 108 selinexor - Drug Profile 109 STD-06 - Drug Profile 114 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 115 TMBP-3 - Drug Profile 117 TP-102 - Drug Profile 118 Vasculotide - Drug Profile 119 Vivefoot - Drug Profile 120 Diabetic Foot Ulcers - Recent Pipeline Updates 121 Diabetic Foot Ulcers - Dormant Projects 138 Diabetic Foot Ulcers - Discontinued Products 141 Diabetic Foot Ulcers - Product Development Milestones 142 Featured News & Press Releases 142 Appendix 148 Methodology 148 Coverage 148 Secondary Research 148 Primary Research 148 Expert Panel Validation 148 Contact Us 148 Disclaimer 149
List of Tables Number of Products under Development for Diabetic Foot Ulcers, H1 2015 12 Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Development by Companies, H1 2015 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H1 2015 18 Comparative Analysis by Late Stage Development, H1 2015 19 Comparative Analysis by Clinical Stage Development, H1 2015 20 Comparative Analysis by Early Stage Development, H1 2015 21 Comparative Analysis by Unknown Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 Diabetic Foot Ulcers - Pipeline by Adocia, H1 2015 27 Diabetic Foot Ulcers - Pipeline by Aprogen, Inc., H1 2015 28 Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 29 Diabetic Foot Ulcers - Pipeline by Celgene Corporation, H1 2015 30 Diabetic Foot Ulcers - Pipeline by CoDa Therapeutics, Inc., H1 2015 31 Diabetic Foot Ulcers - Pipeline by CytoTools AG, H1 2015 32 Diabetic Foot Ulcers - Pipeline by Derma Sciences, Inc., H1 2015 33 Diabetic Foot Ulcers - Pipeline by Dipexium Pharmaceuticals LLC, H1 2015 34 Diabetic Foot Ulcers - Pipeline by EyeGene, Inc., H1 2015 35 Diabetic Foot Ulcers - Pipeline by FirstString Research, Inc., H1 2015 36 Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline plc, H1 2015 37 Diabetic Foot Ulcers - Pipeline by Innovaxis, H1 2015 38 Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corporation, H1 2015 39 Diabetic Foot Ulcers - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 40 Diabetic Foot Ulcers - Pipeline by Kasiak Research Pvt. Ltd., H1 2015 41 Diabetic Foot Ulcers - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2015 42 Diabetic Foot Ulcers - Pipeline by Lytix Biopharma AS, H1 2015 43 Diabetic Foot Ulcers - Pipeline by MacroCure Ltd., H1 2015 44 Diabetic Foot Ulcers - Pipeline by MediaPharma s.r.l., H1 2015 45 Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2015 46 Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co., Ltd., H1 2015 47 Diabetic Foot Ulcers - Pipeline by Plurogen Therapeutics, Inc., H1 2015 48 Diabetic Foot Ulcers - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 49 Diabetic Foot Ulcers - Pipeline by Royer Biomedical, Inc., H1 2015 50 Diabetic Foot Ulcers - Pipeline by Sanofi, H1 2015 51 Diabetic Foot Ulcers - Pipeline by Stratatech Corporation, H1 2015 52 Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H1 2015 53 Diabetic Foot Ulcers - Pipeline by Tissue Med Biosciences, H1 2015 54 Diabetic Foot Ulcers - Pipeline by USV Limited, H1 2015 55 Diabetic Foot Ulcers - Pipeline by Vyome Biosciences Private Limited, H1 2015 56 Assessment by Monotherapy Products, H1 2015 57 Number of Products by Stage and Target, H1 2015 59 Number of Products by Stage and Mechanism of Action, H1 2015 61 Number of Products by Stage and Route of Administration, H1 2015 63 Number of Products by Stage and Molecule Type, H1 2015 65 Diabetic Foot Ulcers Therapeutics - Recent Pipeline Updates, H1 2015 124 Diabetic Foot Ulcers - Dormant Projects, H1 2015 141 Diabetic Foot Ulcers - Dormant Projects (Contd..1), H1 2015 142 Diabetic Foot Ulcers - Dormant Projects (Contd..2), H1 2015 143 Diabetic Foot Ulcers - Discontinued Products, H1 2015 144
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
